Amneal Pharmaceuticals Q3 2026 Earnings Call Transcript - Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals reported third-quarter 2026 results with revenue of $863 million, up 10% year over year. The company said adjusted EBITDA rose 30% to $207 million, and adjusted EPS increased 53% to $0.26. Management emphasized momentum in biosimilars, complex generics and specialty products, citing progress related to the Kashiv acquisition as it works toward end-to-end biosimilar capabilities. Amneal raised its 2026 outlook, projecting revenue between $3.15 billion and $3.25 billion and adjusted EBITDA between $800 million and $815 million. Operational highlights included a full resumption of operations at an India facility following flooding and FDA approval of lanreotide, described as a complex injectable. The company pointed to expanded capacity in women’s health and specialty segments and mentioned a GLP-1 collaboration with Pfizer.